A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.
Site Search
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
As we look forward to 2018, our President and CEO, Preston W. Campbell, III, M.D., shares a special holiday message to the cystic fibrosis community.
More than 200 CF advocates from 47 states held nearly 400 meetings with members of Congress and their staff, and more than 850 advocates from across the country called their members of Congress as part of the CF Foundation's first March on the Hill online Day of Action.
On Oct. 4, the Warren Alpert Foundation honored five CF scientists, including Dr. Francis Collins, for their trailblazing work in CF research. The Foundation received special acknowledgement for our role in driving this progress, marking the first time that an organization has been recognized by the Alpert Foundation.
The Cystic Fibrosis Foundation is offering two vital resources to support CF families who may be affected by Hurricane Michael.
In the wake of Hurricane Florence, the Cystic Fibrosis Foundation is offering two vital resources to support CF families affected by this hurricane and its surge.